skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines ravulizumabQuestion & answer

ravulizumab · Medicine question

Can ravulizumab cause infusion-related reactions or anaphylaxis?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Ravulizumab may cause systemic infusion-related reactions and allergic or hypersensitivity reactions, including anaphylaxis.

Sources for this answer

Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 11Document updated 17 February 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about ravulizumab

How much polysorbate 80 is contained in each 3 mL and 11 mL vial of Ultomiris (ravulizumab) concentrate for solution for infusion?How much sodium is contained in each 3 mL and 11 mL vial of Ultomiris (ravulizumab) concentrate for solution for infusion?Does Ultomiris (ravulizumab) affect the ability to drive or use machines?How can chronic intravenous immunoglobulin treatment affect ravulizumab concentrations?How long should women of childbearing potential use effective contraception during and after ravulizumab treatment?

ravulizumab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the ravulizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX

Which adults with generalised myasthenia gravis is Ultomiris (ravulizumab) indicated to treat as an add-on to standard therapy?